Iruzid (Hydrochlorothiazide, Lisinopril)

Iruzid is indicated for the management of hypertension, a condition involving elevated systemic arterial pressure.

• Hypertension: reduces elevated blood pressure and helps achieve target levels.
• Essential hypertension: provides combined ACE inhibition and diuresis to improve control.
• Renin‑angiotensin system‑mediated hypertension: offers dual mechanism to lower systolic and diastolic pressures.

• Lisinopril blocks the angiotensin‑converting enzyme, decreasing formation of angiotensin II and reducing vasoconstriction, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, promoting diuresis and lowering plasma volume. The combined actions result in a synergistic reduction of arterial blood pressure.

Iruzid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Cough: dry, persistent cough associated with ACE inhibition.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.
• Fatigue: general feeling of tiredness.

Serious or Rare Side Effects

• Angioedema: swelling of face, lips, tongue, or throat that can compromise breathing.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Acute kidney injury: sudden decline in renal function.
• Hyperkalemia: dangerously high potassium levels.
• Severe dehydration: excessive fluid loss leading to electrolyte disturbances.
• Allergic reactions: rash, itching, or anaphylaxis.

Before initiating Iruzid, several safety considerations should be reviewed.

• Renal function: monitor serum creatinine and eGFR regularly.
• Electrolytes: check potassium and sodium levels, especially in patients on other diuretics.
• Pregnancy: category D; avoid use unless benefits outweigh risks.
• Concurrent ACE inhibitors or ARBs: increased risk of hyperkalemia and renal impairment.
• Diabetes mellitus: monitor blood glucose as diuretics may affect control.
• Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Iruzid can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: risk of hyperkalemia.
• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: additive blood‑pressure lowering may cause hypotension.
• Diabetes medications: diuretic effect may alter glucose control.
• Corticosteroids: may increase sodium retention counteracting diuretic action.